We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Study Shows Predisposed Cancer Factors in Ashkenazi Jewish Women

By LabMedica International staff writers
Posted on 07 Aug 2017
Upon finding additional breast cancer mutations in Ashkenazi Jewish breast cancer patients, a new study suggests that this population of women can benefit from genetic testing for all known breast cancer genes.

There are 3 known founder-mutations in BRCA1 and BRCA2 (BRAC1/2) that severely increase the risk of breast and ovarian cancer in Ashkenazi Jewish women. More...
In the new study, led by Mary-Claire King, PhD, of the University of Washington (Seattle, WA, USA), researchers looked for other BC-predisposing mutations in this population. They performed multiplex genomic sequencing, for all known and candidate breast cancer genes, on DNA from 1,007 women of Ashkenazi Jewish ancestry with breast cancer. Of these 1,007 patients, 903 had none of the 3 BRCA1/2 founder mutations. Of those 903 patients, seven (0.8%) carried a different mutation in BRCA1 or BRCA2 and 31 (3.4%) carried a damaging mutation in another breast cancer gene.

The study notes two limitations, including that they only sequenced genes that were known or suspected to harbor mutations that increase the risk of breast cancer.

The study, by Walsh T et al, was published July 20, 2017, by the journal JAMA Oncology.

Related Links:
University of Washington


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.